Drug Target Equipment & Supplies

AAA brand names for [18F]-choline (FCH). ...

AAA brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog. Neurology, ...

TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a boron delivery ...

Therefore, this technology can be applied in particular to assess compound actions on drug targets, such as G protein-coupled receptors and receptor tyrosine ...

Agonist refers to substances that activate a specific target protein. It can easily be viewed as the opposite of inhibitor. Until now, Deargen's drug-target interaction (DTI) was predicted based on the binding affinity between the substance and the target protein, which causes barrier to distinguish between the inhibition and ...

With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug ...

Trillions of microorganisms colonize the human body and play a central role in health and disease. Symbiotic drugs target bacteria to improve human health while leaving good microbes ...

Identify the mode of action of your compound with NPOT® technology; NPOT technology is a unique heterogeneous assembly method for conducting extensive identification of all proteins (together with their native structure) involved in drug-target ...

COVID-19 Research: Antiviral Drug Target ? The COVID-19 pandemic is caused by infection of SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2, a positive-sense single-stranded RNA virus. The RNA dependent RNA polymerase (RdRp) is a key drug target for this deadly virus. ...

DNA-Encoded Library Technology (DELT) is a fast-growing, cutting-edge discovery technology used to identify small molecule hits or leads against a variety of drug targets. The main principle of DELT is to encode each compound in the library with a unique DNA barcode. Thereby library of billion compounds can be screened as a mix in a single test tube and the ...

Because TGF-β is chronically elevated in many diseases, including ophthalmic and fibrotic diseases and cancer, and involved in their pathophysiology, it is an extremely versatile drug target throughout the body. ...

This strategy is unique and contrasts with established approaches which down-regulate protein production. This platform can lead to the discovery of new drugs to target relevant genes that regulate the optimal production of endogenous functional proteins. One of the leading applications of our AntagoNAT technology is OPK88001 which is designed for the treatment ...

It also identifies the drug and drug targets that modulate specific phenotypes. High Content Phenotypic Screening aims to identify morphological patterns in cell populations and to probe the causes and cures for various ...

AMPPLIFY Drug Delivery Technology is designed to enhance penetration through the mucus barrier and deliver increased concentration of drug to the target ocular tissue. AMPPLIFY Drug Delivery Technology has been shown to improve delivery of loteprednol etabonate compared to traditional suspension eyedrops without ...

G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, ...

Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...

Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory ...

AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. ...

Circumventing drug toxicity and drug resistance is key to effective anticancer therapy. Da Zen’s products and technologies deliver targeted anticancer drugs, such as simvastatin and cisplatin conjugated to a cancer targeting dye-carrier, exclusively to cancer cells, with the drugs confined ...

BA9, an effective Cytostatic Limus Drug: Rapid 28 day BA9 transfer to the vessel wall achieved through enhanced high lipophilicity delivering: Greater Local Bioavailability. Targeted Drug Release. Local tissue warehousing allowing Sustained Tissue Release, with Therapeutic Effect up to 100 days12,13. ...